NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I know some here have differing positions on how the initial stages of the combination trial were designed. That said, I think the early results simply combine DCVax-l plus Keytruda. With that alone, in recurrent glioblastoma, the survival seems it will continue at around or above 45% for an unprecedented time. Even if it slips below that, it’s still remarkable.

Still, imho, that’s just the beginning. Now adding poly iclc, that survival tail may trend around or above 55% for an unprecedented time.

Finally, adding the fourth component to the combination trial, csf1r, may get that long tail above 75%

These are just my educated guesses.

The keystone is DCVax-l, because without it, directing sufficient functional cytotoxic t-cells into the cancerous tumor is effectively impossible.